Filing Details
Barinthus Biotherapeutics plc. (NASDAQ:BRNS) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 06, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:BRNS
Barinthus Biotherapeutics plc. (BRNS) Files Quarterly Report for Q0
Filing Details Barinthus Biotherapeutics plc. (NASDAQ:BRNS) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 06, 2026. The Healthcare…
Market Context
Barinthus Biotherapeutics plc.'s stock currently trades at $0.56 with a market capitalization of $29.6M.
The 10-Q provides Barinthus Biotherapeutics plc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Barinthus Biotherapeutics plc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View BRNS Stock Page
Frequently Asked Questions
Where can I read BRNS's SEC filings?
Browse all filings on our BRNS SEC filings page.
What types of SEC filings does Barinthus Biotherapeutics plc. file?
Public companies like Barinthus Biotherapeutics plc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.